Loading
Eupraxia Pharmaceuticals Inc. Stock: price and insider trades · Canada
Eupraxia Pharmaceuticals Inc.: what insiders have been doing
Eupraxia Pharmaceuticals Inc. is a Health Care company. Its directors and officers file their transactions with SEDI. The last twelve months, up to 24 October 2026, brought 83 filings signed by 13 insiders.
The record shows 19 purchases on the open market worth €379k, made by 4 insiders, against 1 sale worth €103k by 1 insider. Taken together, the purchases exceed the sales by €277k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a sale of €103k by Geyer, Paul, published on 18 March 2026. The buyers include 4 senior executives.
The clock since the last published purchase (19 August 2026) now reads 67 days. Between a trade and the moment it shows up on SEDI, the median delay is 3 days. That lag is the time during which only the insider knows about the trade.
For context, the typical company on the same exchange (median of 2,734 companies) published 14 filings over the same period, against 83 filings here. Our records for Eupraxia Pharmaceuticals Inc. go back to 2021, with 71 purchases and 1 sale on the open market in total.
This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Insider Decl.
193
Thresholds
n/a
Buy Volume
€2M
71 ops. · all time
Sell Volume
€102,535
1 ops. · all time
Who traded when
BuySaleJoseph Stuart Freedman17 buys
Simon Neil Pimstone5 buys
Paul Anthony Brennan4 buys
John Montalbano1 buy
Paul Geyer1 sale
Richard Glickman1 buy
Analyst consensus: bullish or bearish?
Analysts rate Eupraxia Pharmaceuticals Inc. Strong Buy (bullish), based on 3 analysts. Average price target: CA$16.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$9.57
Analyst consensus
3 analystsStrong buy
CA$14.00Target CA$16.33(+71%)CA$18.00
Income statement
EBITDA-CA$38.3M
Net income-CA$38.6M0.0% margin
Valuation
PER (forward)-6.5x
P/Book4.4x
Beta1.22
Balance sheet & cash
Market capCA$632.3M
Total debtCA$154.4k
Free Cash Flow-CA$29.1M
Debt / Equity1%
Profitability & ownership
ROE-66.7%
ROA-43.7%
% insiders12.1%
% institutions43.3%
Last declaration on 25 September 2026
Declarations193 total
1,602,580 sharesCommon SharesTSXSEDI:4781966
Common SharesTSXSEDI:4781965
387,300 sharesCommon SharesTSXSEDI:4781964
1,215,280 sharesCommon SharesTSXSEDI:4781963
1,493,985 sharesConvertible Preferred Shares Series 1TSXSEDI:4781962
1,200,000 sharesConvertible Preferred Shares Series 1TSXSEDI:4781961
460,000 sharesConvertible Preferred Shares Series 1TSXSEDI:4781960
3,153,985 sharesConvertible Preferred Shares Series 1TSXSEDI:4781959
Convertible Preferred Shares Series 1TSXSEDI:4781958
22,000 shares@ CA$6.81970.020% mcap63.5% of flowCommon SharesTSXSEDI:4766116
Canonical exit: 17 Nov 2026 (T+90)
2,000 sharesCommon SharesTSXSEDI:4765487
5 sharesCommon SharesTSXSEDI:4765486
200 sharesCommon SharesTSXSEDI:4765485
20,000 sharesRights Restricted Stock UnitTSXSEDI:4754031
Rights Restricted Stock UnitTSXSEDI:4754030
40,000 shares@ CA$9.46100.0% of flowOptionsTSXSEDI:4754029
OptionsTSXSEDI:4754028
Common SharesTSXSEDI:4741824
Common SharesTSXSEDI:4741822
50,000 sharesRights Restricted Stock UnitTSXSEDI:4741818
160,000 shares@ CA$8.89100.0% of flowOptionsTSXSEDI:4741813
20,000 sharesRights Restricted Stock UnitTSXSEDI:4741808
Rights Restricted Stock UnitTSXSEDI:4741807
40,000 shares@ CA$8.89100.0% of flowOptionsTSXSEDI:4741801
OptionsTSXSEDI:4741799
25 of 193 declarations
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases and musculoskeletal disorders. It is listed on the XTSE market.
